Literature DB >> 6574831

Busulfan kinetics.

H Ehrsson, M Hassan, M Ehrnebo, M Beran.   

Abstract

Busulfan kinetics were studied in patients with chronic myelocytic leukemia after oral doses of 2, 4, and 6 mg. The plasma concentration-time data could be fitted to a zero-order absorption one-compartment open model. The elimination rate constant averaged 0.27 +/- 0.05 hr-1 (SD). The plasma AUC was linearly related to the dose. The lag time for the start of absorption, the time absorption ends, and the absorption rate constant showed some interindividual variations. About 1% of busulfan is excreted unchanged in urine over 24 hr.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6574831     DOI： 10.1038/clpt.1983.134

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  18 in total

1.  The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity.

Authors:  W E Fitzsimmons; R Ghalie; H Kaizer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

4.  Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Authors:  Yvonne S Lin; Savannah J Kerr; Timothy Randolph; Laura M Shireman; Tauri Senn; Jeannine S McCune
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

Review 5.  Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Authors:  J S McCune; J P Gibbs; J T Slattery
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

6.  Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.

Authors:  Edward A Copelan; Belinda R Avalos; Kwang Woo Ahn; Xiaochun Zhu; Robert Peter Gale; Michael R Grunwald; Mehdi Hamadani; Betty K Hamilton; Gregory A Hale; David I Marks; Edmund K Waller; Bipin N Savani; Luciano J Costa; Muthalagu Ramanathan; Jean-Yves Cahn; H Jean Khoury; Daniel J Weisdorf; Yoshihiro Inamoto; Rammurti T Kamble; Harry C Schouten; Baldeep Wirk; Mark R Litzow; Mahmoud D Aljurf; Koen W van Besien; Celalettin Ustun; Brian J Bolwell; Christopher N Bredeson; Omotayo Fasan; Nilanjan Ghosh; Mary M Horowitz; Mukta Arora; Jeffrey Szer; Alison W Loren; Edwin P Alyea; Jorge Cortes; Richard T Maziarz; Matt E Kalaycio; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-17       Impact factor: 5.742

7.  Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.

Authors:  Nissa Abbasi; Barbara Vadnais; Jennifer A Knutson; David K Blough; Edward J Kelly; Paul V O'Donnell; H Joachim Deeg; Matthew A Pawlikowski; Rodney J-Y Ho; Jeannine S McCune
Journal:  J Clin Pharmacol       Date:  2010-12-06       Impact factor: 3.126

8.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

9.  Disposition of total and unbound etoposide following high-dose therapy.

Authors:  T L Schwinghammer; R A Fleming; C S Rosenfeld; D Przepiorka; R K Shadduck; E J Bloom; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.

Authors:  F Léger; L Nguyen; C Puozzo
Journal:  Eur J Clin Pharmacol       Date:  2009-05-08       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.